IL6 and Cachexia: Conversely, blocking IL-6 with a neutralizing monoclonal antibody or with sulindac, a nonsteroidal anti-inflammatory drug (NSAID), reduces the severity of cachexia and suppresses the browning capacity of subcutaneous WAT (Petruzzelli et al. 2014).